- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Frontiers in molecular biosciences, 7, Article 84, S. 84-1-84-9
- Event
-
Veröffentlichung
- (where)
-
Bochum
- (who)
-
Ruhr-Universität Bochum
- (when)
-
2020
- Creator
-
Mika, Thomas
Maghnouj, Abdelouahid
Klein-Scory, Susanne
Ladigan, Swetlana
Baraniskin, Alexander
Thomson, Julia
Hasenkamp, Justin
Hahn, Stephan
Wulf, Gerald
Schroers, Roland
- URN
-
urn:nbn:de:hbz:294-73962
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mika, Thomas
- Maghnouj, Abdelouahid
- Klein-Scory, Susanne
- Ladigan, Swetlana
- Baraniskin, Alexander
- Thomson, Julia
- Hasenkamp, Justin
- Hahn, Stephan
- Wulf, Gerald
- Schroers, Roland
- Ruhr-Universität Bochum
Time of origin
- 2020
Other Objects (12)
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas